SANT 2

• Description:

  SANT 2 is a potent Hh-signaling pathway antagonist. SANT 2 interferes with the expression of Gli1. SANT 2 causes developmental delay in medaka embryos. SANT 2 has the potential for the research of several malignancies including Gorlin syndrome (a disorder predisposing to basal cell carcinoma, medulloblastoma and rhabdomyosarcoma), prostate, pancreatic and breast cancers[1][2].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319

• Target:

  Gli; Hedgehog

• Type:

  Reference compound

• Related Pathways:

  Stem Cell/Wnt

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/sant-2.html

• Purity:

  99.41

• Solubility:

  DMSO : 250 mg/mL (ultrasonic)

• Smiles:

  ClC1=CC=C(NC(C2=CC(OCC)=C(OCC)C(OCC)=C2)=O)C=C1C3=NC4=CC=CC=C4N3

• Molecular Formula:

  C26H26ClN3O4

• Molecular Weight:

  479.96

• Precautions:

  H302, H315, H319

• References & Citations:

  [1]Büttner A, et al. Synthesis and biological evaluation of SANT-2 and analogues as inhibitors of the hedgehog signaling pathway. Bioorg Med Chem. 2009 Jul 15;17 (14) :4943-54.|[2]Rominger CM, et al. Evidence for allosteric interactions of antagonist binding to the smoothened receptor. J Pharmacol Exp Ther. 2009 Jun;329 (3) :995-1005.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  329196-48-7